Roche in India

For more than 60 years, Roche has been committed to making a difference to the lives of people in India. From vitamins in the late 1950s to the advanced medicines for treating different forms of cancer today, we have worked hard to bring the most innovative and path-breaking drugs to Indian patients.

Today, Roche is the leader in oncology treatment in India; apart from cancer, Roche’s has innovative medicines in other therapy areas too: transplantation, rheumatoid arthritis (RA), and chronic kidney disease (CKD)-related anaemia. We believe in making the latest and most innovative medicines accessible to patients in India in the fastest possible time. 

Our vision is to inspire people to transform healthcare and care for every patient’s life through sustainable, innovative solutions. Given the scale and size of India’s healthcare challenges, we believe transformation is the only way to address them: transformative medicines, transforming access and delivery systems, and transforming the way we do business in India.

The healthcare challenges that India faces are as varied and complex as the country is heterogenous and huge. Non-communicable diseases (NCDs) account for nearly 60 out of every 100 deaths in India, every year, in both rural (where most of the population lives) and urban India. The incidence and distribution of NCDs varies across states and regions.

To address these challenges, we at Roche bring the main driving force of our company – innovation – to help create long-term sustainable solutions across the value chain. We practice innovation in India by creating access to our portfolio of innovative medicines using an innovative strategy to reach patients who need those medicines.

Patient-centricity remains at the core of our business philosophy. Simply put, this means that at Roche, we put the patient at the centre of everything that we do. In doing that, our orientation is towards being a value affiliate, not a commercial one. As an organisation we measure our success by the number of patient lives we touch, and can positively impact.

Our idea of access goes beyond just access to medicines. We believe in supporting the patient through the entire process: from awareness, through diagnosis and access to infrastructure, to making the tough decisions about treatment options. Support extends all the way through to help in adherence to the treatment regimen.

To this end, Roche India developed The Blue Tree programme. This single platform supports patients and their families with disease awareness and testing, funding solutions, home delivery of medicines, free medicines, treatment adherence support and standardised reports. The programme’s support also extends to patients’ families. The Blue Tree programme was showcased as an effective and unique patient support programme (PSP) at the United General Assembly (UNGA) Week – as part of the 72nd Session of the UNGA in September 2017. Since its launch, it has benefited more than 7,000 of patients.

Roche’s impact goes beyond just healthcare in India. Our investments have created more than 2,500 full-time jobs with some of our strategic partners including leading IT service providers.